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Evidence suggests that cystic ﬁbrosis liver disease (CFLD) does not impact on
mortality or morbidity in CF. The aim of this study was to review children enrolled
in a study of CFLD in 1999–2000.
Methods: Participants were reviewed clinically and radiologically. 3 participants
(2 cases, 1 control) were lost to follow-up, 1 control refused, and 8 partici-
pants(5 cases) were excluded.
Results: There was no difference in age, (mean 19.9±3.2 yrs) duration of follow-
up (76.9±20.2mths), gender(63% male) between cases and controls. 7 patients
with CFLD died (3 liver failure) 1 liver transplant, and 3 controls died. Crude
mortality for patients with CFLD was 11.3/1000 person yrs of age (95%CI
3.5−19.0) compared to 4.1/1000 (95% CI 0.6−8.9) for controls. Patients with liver
disease died younger (median 17.5 yrs V 21.5 (p = 0.06). There was no difference
in height, weight or BMI between the groups. Nutritional parameters (sum skin
fold thickness 30.1±17.4 V 38.1±21.2 p = 0.03), Shwachman score (49.1±11.4
V 55.4±12.5 p = 0.02) were poorer in patients with CFLD. They had a higher
proportion of CF Diabetes Mellitus (40.7% V 15.2% p= 0.02). 9 children with
evidence (clinical/radiological) of liver disease at baseline, had no evidence of
portal hypertension as adults.
Conclusion: Patients with CFLD may have a higher mortality and die younger
than CF patients without liver disease. However some children with CFLD will not
manifest clinically signiﬁcant liver disease as adults.
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Objectives: Liver disease is a major complication of cystic ﬁbrosis and is generally
seen within the ﬁrst ten years of life. The aim of this study was to evaluate a blood
test, the FibroMeter, to detect liver ﬁbrosis or cirrhosis in children with cystic
ﬁbrosis.
Population and Methods: Fifty-one children with ages ranging from 1 to 18 years
were included in this study between September 2007 and September 2008. All were
followed by the Cystic Fibrosis Center at the University Hospital in Angers, France.
The children were staged into one of four groups on the basis of their biological
and ultrasound results. The results of liver biology, ultrasonography, the FibroMeter
test, and transient elastometry were compared.
Results: The FibroMeter results in the children without liver disease or elevated
g-glutamyltransferase and without abnormal ultrasound were signiﬁcantly better
than those with clear cirrhosis or an abnormal ultrasound. Of the 33 children that
had transient elastometry, only two had results above 7 kPa, whereas eight had an
abnormal ultrasound.
Conclusion: The FibroMeter could be useful in detecting children at risk of
developing ﬁbrosis or cirrhosis. Transient elastometry assesses the degree of ﬁbrosis
in patients but does not seem to be an effective tool to detect liver ﬁbrosis. These
results will have to be conﬁrmed by longitudinal study of these children.
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TGF-b are cytokines that regulate proliferation and differentiation of cells. Dys-
regulation of the TGF-b pathway may modulate the development of severe dis-
ease groups including hepatic ﬁbrosis. TGF-b signals through the transmembrane
receptor serine/threonine kinase to activate SMAD proteins, which modulate the
transcription of target genes. The aim of this study was to investigate the correlation
of hepatic tissue TGF-b1, TGF-b3, ALK5 and Smad 2, 3, 4 with the degree of liver
involvement in cystic ﬁbrosis (CF).
Methods: Eleven CF patients underwent percutaneous liver biopsy. The biopsy
needle was directed to the site of the lesion under CT scan. Fibrosis was graded
as 0 (normal), 1, 2 and 3 (mild to moderate). Two groups were studied: Group A:
6 CF patients having normal liver (ﬁbrosis 0) and mean age of 11.2 years, and
Group B: 5 CF patients having mild to moderate ﬁbrosis (1, 2, 3) and mean age of
15.0 years.
Results: The mean rank of TGF-b1, TGF-b3, ALK 5, SMAD 2, 3, 4 was 6.40, 7.80,
7.40, 7.60, 7.20, 7.60, respectively, in group B as opposed to 5.67, 5.17, 4.33, 4.83,
4.67, 4.67 in group A. Hepatic tissue mean cytokine values tended to be higher in
the ﬁbrotic liver as compared to normal liver.
Conclusion: Hepatic ﬁbrosis increased with age in CF. TGF-b and SMAD proteins
were increased in the presence of ﬁbrosis at histology. The differences did not
reach statistical signiﬁcance, probably, due to the small number of individuals.
These cytokines may be involved in the reactive ﬁbrosing process of the liver.
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It seems that immunity play an important role in CF-related liver disease’s out-
come. If the immune deﬁciencies or autoimmunity are the causes remain to be
demonstrated.
Aim study was to asses the inﬂuence of humoral immunity on liver disease of
CF patients. Material and method: 27 patients, age 3−21 years, with cystic ﬁbrosis
associated liver disease (CFLD) and normal liver function, were considered for
study. Inclusion criteria: D F508 homozygous genotype, good respiratory and
nutrition status; patients with immunodeﬁciency, hypoalbuminemia, pulmonary
chronic infection, hepatotoxic treatment history or hepatitis were excluded. Serum
levels of immunoglobulin A, M, G, MBL (mannose binding lectine) and protein
electrophoresis were evaluated. Results: Combined Ig deﬁciency was registered in
26% CFLD patients, 14.8% had selective deﬁcit in IgA. Only 8 patients (29.6%) had
normal immunoglobulin values, but 3 of them MBL deﬁcient. Low MBL level were
found in 44.4%-12 pts (8 with other immunodeﬁciency); protein electrophoresis
showed increase gglobulin level in 41.6% (5 pts) of MBL deﬁcient patients. Only
18% had normal immunoglobulin and MBL levels.
Conclusion: Large percentage of immunoglobulin and MBL deﬁcit among patients
with CFLD sustain the association between immune deﬁciencies and occurrence
of associated liver disease in cystic ﬁbrosis patients. In which way the diseases
inﬂuence each other remain to be documented by more studies.
